Search Within

Paul K Paik

Formats
  1. Meeting Abstract (168)
  2. Journal Article (85)
  3. Review (5)
  4. Book Section (1)
Groups
  1. Department of Medicine (259)
  2. Solid Tumor Oncology Division (259)
  3. Thoracic Oncology (259)
  4. GSK Faculty (77)
  5. Department of Pathology and Laboratory Medicine (73)
  6. Human Oncology and Pathogenesis Program (55)

More Groups

People
  1. Mark Kris (55)
  2. Marc Ladanyi (47)
  3. Gregory Riely (42)
  4. Natasha Rekhtman (41)
  5. Charles Rudin (40)
  6. Jamie Chaft (34)

More People

Years
  1. 2025 (9)
  2. 2024 (15)
  3. 2023 (32)
  4. 2022 (39)
  5. 2021 (34)
  6. 2020 (18)

More Years

Publications
  1. Journal of Thoracic Oncology (60)
  2. Journal of Clinical Oncology (49)
  3. Annals of Oncology (34)
  4. Clinical Cancer Research (13)
  5. International Journal of Radiation Oncology, Biology, Physics (11)
  6. Clinical Lung Cancer (6)

More Publications

Publishers
  1. Elsevier Inc. (82)
  2. American Society of Clinical Oncology (56)
  3. Oxford University Press (38)
  4. American Association for Cancer Research (23)
  5. Wiley Blackwell (12)
  6. Nature Publishing Group (11)

More Publishers

Results (259)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs)
    Meeting Abstract

    Sato, H.; Kubota, D.; Paik, P. K.; Qiao, H.; Jungbluth, A. A.; Rekhtman, N.; Schoenfeld, A. J.; Yu, H. A.; Riely, G. J.; Lovly, C. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Liquid biopsy to detect MET exon 14 skipping (METex14) and MET amplification in patients with advanced NSCLC: Biomarker analysis from VISION study
    Meeting Abstract

    Le, X.; Kowalski, D.; Cho, B. C.; Conte, P.; Felip, E.; Garassino, M. C.; Viteri, S.; Chang, G. C.; Richart, J.; Paz-Ares, L.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Real-world insights into patients (pts) with advanced NSCLC and MET alterations
    Meeting Abstract

    Bittoni, M.; Yang, J. C. H.; Shih, J. Y.; Peled, N.; Smit, E.; Camidge, R.; Carbone, D.; Oksen, D.; Boutmy, E.; Johne, A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
    Meeting Abstract

    Yang, J. C. H.; Le, X.; Cho, B. C.; Han, J. Y.; Morise, M.; Chen, Y. M.; Kang, J. H.; Kato, T.; Takeoka, H.; Chikamori, K.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations
    Meeting Abstract

    Paik, P. K.; Ahn, L. S. H.; Plodkowski, A. J.; Fan, P. D.; Rudin, C. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with NSCLC with MET exon 14 (METex14) skipping: Health-related quality of life (HRQoL)
    Meeting Abstract

    Paik, P. K.; Horn, L.; Kowalski, D. M.; Patel, J. D.; Griesinger, F.; Han, J. Y.; Smit, E. F.; Kato, T.; Le, X.; Scheele, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping
    Meeting Abstract

    Le, X.; Felip, E.; Veillon, R.; Sakai, H.; Cortot, A. B.; Garassino, M. C.; Mazieres, J.; Ramirez, S. V.; Senellart, H.; Van Meerbeeck, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
    Meeting Abstract

    Garassino, M. C.; Le, X.; Kowalski, D. M.; Migliorino, M. R.; Senellart, H.; Fuentes Pradera, J.; Walling, R.; Kato, T.; Thomas, M.; Smit, E. F.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A
    Meeting Abstract

    Mazieres, J.; Paik, P. K.; Felip, E.; Veillon, R.; Sakai, H.; Cortot, A. B.; Viteri, S.; Garassino, M. C.; Van Meerbeeck, J. P.; Raskin, J.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Viteri, S.; Mazieres, J.; Veillon, R.; Felip, E.; Le, X.; Garassino, M. C.; Stanton, T. S.; Morise, M.; Lee, J. S.; Matsumoto, S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save